Company: BDRX
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001214659-25-000306
Chunk: 108

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-08
Form: 424B3
Chunk 108
---
 the Company and its Subsidiaries
is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification. The Company has no Subsidiaries required to be disclosed pursuant to Item 601(b)(21)(ii) of Regulation S-K, except as
set forth in the Company’s Annual Report on Form 20-F for its fiscal year ended December 21, 2023 filed with the Commission on April
19, 2024.

(b) . (i) The Company has the requisite corporate power and authority to enter into and (subject to any applicable
rules and regulations of the Principal Market) perform its obligations under this Note and each of the other Transaction Documents in
accordance with the terms hereof and thereof, (ii) the execution and delivery of this Note and each of the other Transaction Documents
by the Company and the consummation by it of the transactions contemplated hereby and thereby, have been duly authorized by the Company’s
Board of Directors (the “”) and no further consent or authorization is required by the Company, its
Board of Directors or its stockholders, (iii) as of the Issuance Day, this Note shall be duly executed and delivered by the Company and
(iv) this Note, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding
obligations of the Company enforceable against the Company in accordance with their terms, except as such enforceability may be limited
by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or other laws relating to,
or affecting generally, the enforcement of creditors’ rights and remedies. The Board of Directors has approved the resolutions (the
“”) substantially in the form provided to the Holder to authorize this Note and the transactions
contemplated hereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any respect.
The Company has delivered to the Holder a true and correct copy of minutes of a meeting